NO3004079T3 - - Google Patents
Info
- Publication number
- NO3004079T3 NO3004079T3 NO14727562A NO14727562A NO3004079T3 NO 3004079 T3 NO3004079 T3 NO 3004079T3 NO 14727562 A NO14727562 A NO 14727562A NO 14727562 A NO14727562 A NO 14727562A NO 3004079 T3 NO3004079 T3 NO 3004079T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1350685 | 2013-06-04 | ||
PCT/EP2014/061503 WO2014195323A1 (fr) | 2013-06-04 | 2014-06-03 | Composés de pyrimidine et leur utilisation comme modulateurs de la gamma-sécrétase |
Publications (1)
Publication Number | Publication Date |
---|---|
NO3004079T3 true NO3004079T3 (fr) | 2018-06-16 |
Family
ID=50877325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO14727562A NO3004079T3 (fr) | 2013-06-04 | 2014-06-03 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9439904B2 (fr) |
EP (1) | EP3004079B1 (fr) |
JP (1) | JP6368777B2 (fr) |
CN (1) | CN105263923B (fr) |
DK (1) | DK3004079T3 (fr) |
ES (1) | ES2665421T3 (fr) |
NO (1) | NO3004079T3 (fr) |
PL (1) | PL3004079T3 (fr) |
WO (1) | WO2014195323A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3481829B1 (fr) * | 2016-07-08 | 2021-04-07 | H. Hoffnabb-La Roche Ag | Dérivés fusionnés de pyrimidine |
CN108191776A (zh) * | 2018-01-22 | 2018-06-22 | 无锡富泽药业有限公司 | 一种尿嘧啶的绿色生产工艺 |
WO2020247707A1 (fr) * | 2019-06-05 | 2020-12-10 | Chunyu Wang | SYSTÈME ET PROCÉDÉ D'INHIBITION DE LA PRODUCTION DE γ-SÉCRÉTASE ET DE PEPTIDES β-AMYLOÏDES |
CN110372603A (zh) * | 2019-06-24 | 2019-10-25 | 南京普锐达医药科技有限公司 | 一种2-氯-5-氟-6-乙基嘧啶的合成方法 |
IL306008A (en) | 2021-03-23 | 2023-11-01 | Halia Therapeutics Inc | Pyrimidine derivatives are useful as LRRK2 kinase inhibitors |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2348234A1 (fr) * | 1998-10-29 | 2000-05-11 | Chunjian Liu | Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh |
ITMI20030312A1 (it) | 2003-02-21 | 2004-08-22 | Chiesi Farma Spa | Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer. |
ATE464048T1 (de) | 2003-08-07 | 2010-04-15 | Merck Sharp & Dohme | Behandlung von alzheimer-krankheit und verwandten zuständen |
US20070142453A1 (en) | 2003-12-03 | 2007-06-21 | Dirk Beher | 1-Alkyl-3-thio-substituted indole-2-alkynoic acids useful for the treatment of alzheimer's disease and related conditions |
EP2261218B1 (fr) | 2004-05-26 | 2013-04-03 | Eisai R&D Management Co., Ltd. | Imidazolverbindung zur Verwendung als Intermediat in der Herstellung von Cinnamid-Verbindungen |
CN103626742B (zh) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
US8389547B2 (en) | 2006-04-26 | 2013-03-05 | Yudith Garcia | Piperidines and related compounds for the treatment of Alzheimer's disease |
WO2007135969A1 (fr) | 2006-05-19 | 2007-11-29 | Eisai R & D Management Co., Ltd. | Dérivé de cinnamide de type urée |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
JP2010518080A (ja) | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療薬 |
WO2008100412A1 (fr) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Dérivés de la pipéridine |
EP2121633A2 (fr) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Dérivés de pipérazine pour le traitement de la maladie d'alzheimer et des conditions apparentées |
US8242150B2 (en) | 2007-06-13 | 2012-08-14 | Merck Sharp & Dohme Corp. | Triazole derivatives for treating alzheimer'S disease and related conditions |
PE20090957A1 (es) | 2007-08-06 | 2009-07-13 | Schering Corp | Moduladores de gamma secretasa |
BRPI0906799A2 (pt) | 2008-01-11 | 2015-07-14 | Hoffmann La Roche | Moduladores para amiloide beta |
AU2009216851B2 (en) * | 2008-02-22 | 2013-11-07 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
MX2011003246A (es) * | 2008-10-09 | 2011-04-21 | Hoffmann La Roche | Moduladores de beta amiloide. |
AU2009311756B2 (en) * | 2008-11-06 | 2012-05-03 | Astrazeneca Ab | Modulators of amyloid beta. |
EP2355817A1 (fr) | 2008-11-10 | 2011-08-17 | F. Hoffmann-La Roche AG | Modulateurs de la gamma secrétase hétérocyclique |
TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
UY32622A (es) * | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
EA021047B1 (ru) | 2009-07-15 | 2015-03-31 | Янссен Фармасьютикалз, Инк. | Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы |
TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
KR20130028048A (ko) | 2010-01-15 | 2013-03-18 | 얀센 파마슈티칼즈, 인코포레이티드 | 감마 세크레타제 조절제로서의 신규 치환된 트리아졸 유도체 |
US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
TW201206946A (en) | 2010-07-15 | 2012-02-16 | Bristol Myers Squibb Co | Compounds for the reduction of beta-amyloid production |
-
2014
- 2014-06-03 NO NO14727562A patent/NO3004079T3/no unknown
- 2014-06-03 CN CN201480032083.0A patent/CN105263923B/zh not_active Expired - Fee Related
- 2014-06-03 EP EP14727562.2A patent/EP3004079B1/fr active Active
- 2014-06-03 JP JP2016517275A patent/JP6368777B2/ja not_active Expired - Fee Related
- 2014-06-03 PL PL14727562T patent/PL3004079T3/pl unknown
- 2014-06-03 WO PCT/EP2014/061503 patent/WO2014195323A1/fr active Application Filing
- 2014-06-03 US US14/895,528 patent/US9439904B2/en not_active Expired - Fee Related
- 2014-06-03 ES ES14727562.2T patent/ES2665421T3/es active Active
- 2014-06-03 DK DK14727562.2T patent/DK3004079T3/en active
Also Published As
Publication number | Publication date |
---|---|
JP6368777B2 (ja) | 2018-08-01 |
EP3004079A1 (fr) | 2016-04-13 |
JP2016520637A (ja) | 2016-07-14 |
PL3004079T3 (pl) | 2018-07-31 |
CN105263923A (zh) | 2016-01-20 |
US9439904B2 (en) | 2016-09-13 |
CN105263923B (zh) | 2017-06-23 |
DK3004079T3 (en) | 2018-04-16 |
ES2665421T3 (es) | 2018-04-25 |
US20160129002A1 (en) | 2016-05-12 |
EP3004079B1 (fr) | 2018-01-17 |
WO2014195323A1 (fr) | 2014-12-11 |